Resistance to taxane chemotherapy is frequently observed in metastatic prostate cancer. The androgen receptor (AR) is a major driver of prostate cancer and a key regulator of the G1–S cell-cycle checkpoint, promoting cancer cell proliferation by irreversible passage to the S-phase. We hypothesized that AR signaling inhibitor (ARSi) darolutamide in combination with docetaxel could augment antitumor effect by impeding the proliferation of taxane-resistant cancer cells. We monitored cell viability in organoids, tumor volume, and PSA secretion in patient-derived xenografts (PDX) and analyzed cell cycle and signaling pathway alterations. Combination treatment increased antitumor effect in androgen-sensitive, AR-positive prostate cancer organoids and PDXs. Equally beneficial effects of darolutamide added to docetaxel were observed in a castration-resistant model, progressive on docetaxel, enzalutamide, and cabazitaxel. In vitro studies showed that docetaxel treatment with simultaneous darolutamide resulted in a reduction of cells entering the S-phase in contrast to only docetaxel. Molecular analysis in the prostate cancer cell line LNCaP revealed an upregulation of cyclin-dependent kinase inhibitor p21, supporting blockade of S-phase entry and cell proliferation. Our results provide a preclinical support for combining taxanes and darolutamide as a multimodal treatment strategy in patients with metastatic prostate cancer progressive on ARSi and taxane chemotherapy.
Combination of docetaxel and darolutamide in C4-2B4 and LNCaP. Dose-response curve with mean normalized viability (+/- SEM) of two (A-B) or three (C-D) separate experiments with technical triplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.
Combination of docetaxel and darolutamide in PC346C-Enzalutamide resistant cells. A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.
Darolutamide and docetaxel pharmacokinetics in PC346C bearing mice, related to Figure 2A-C. A: Mean systemic darolutamide concentrations in PC346C bearing mice treated with darolutamide, with or without docetaxel (n=8 and n=9 per group, respectively) directly after oral darolutamide administration at treatment initiation (start), 2 weeks or 4 weeks after treatment initiation and at time of mouse sacrifice (end). B: Mean systemic docetaxel concentrations in PC346C bearing mice treated with docetaxel, with or without darolutamide (n=8 per group) directly after i.v. docetaxel administration.